CL2017001488A1 - Benzamidas sustituidas con 1,3–tiazol–2–ilo - Google Patents
Benzamidas sustituidas con 1,3–tiazol–2–iloInfo
- Publication number
- CL2017001488A1 CL2017001488A1 CL2017001488A CL2017001488A CL2017001488A1 CL 2017001488 A1 CL2017001488 A1 CL 2017001488A1 CL 2017001488 A CL2017001488 A CL 2017001488A CL 2017001488 A CL2017001488 A CL 2017001488A CL 2017001488 A1 CL2017001488 A1 CL 2017001488A1
- Authority
- CL
- Chile
- Prior art keywords
- thiazol
- compounds
- benzamides substituted
- benzamides
- substituted
- Prior art date
Links
- -1 1,3-thiazol-2-yl Chemical group 0.000 title 1
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000003936 benzamides Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
<p>COMPUESTOS DE BENZAMIDAS SUSTITUIDAS CON 1,3–TIAZOL–2–ILO DE LA FÓRMULA GENERAL (I) QUE SE DESCRIBEN Y DEFINEN EN LA PRESENTE, CON COMPOSICIONES Y COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS Y CON EL USO DE DICHOS COMPUESTOS EN LA ELABORACIÓN DE UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO O LA PROFILAXIS DE UNA ENFERMEDAD, EN PARTICULAR DE UN TRASTORNO NEUROGÉNICO, YA SEA COMO AGENTE ÚNICO O EN COMBINACIÓN CON OTROS INGREDIENTES ACTIVOS.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196954 | 2014-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001488A1 true CL2017001488A1 (es) | 2018-02-23 |
Family
ID=52015966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001488A CL2017001488A1 (es) | 2014-12-09 | 2017-06-09 | Benzamidas sustituidas con 1,3–tiazol–2–ilo |
Country Status (42)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24411B1 (es) * | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN106588785A (zh) * | 2016-12-02 | 2017-04-26 | 山东吉田香料股份有限公司 | 一种乙酰基吡嗪的制备方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| SG11202011010YA (en) * | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| CN113164488A (zh) | 2018-10-05 | 2021-07-23 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| DK3880678T3 (da) | 2018-11-13 | 2025-06-10 | Glaxosmithkline Intellectual Property No 3 Ltd | Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| WO2020201398A1 (en) | 2019-04-05 | 2020-10-08 | Syngenta Crop Protection Ag | Pesticidally active diazine-amide compounds |
| WO2020208036A1 (en) * | 2019-04-11 | 2020-10-15 | Syngenta Crop Protection Ag | Pesticidally active diazine-amide compounds |
| KR102923602B1 (ko) | 2019-05-31 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 피리도피리미딘 유도체 |
| MA56022A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
| WO2021238834A1 (zh) * | 2020-05-25 | 2021-12-02 | 中国医药研究开发中心有限公司 | 芳甲酰胺类化合物及其制备方法和医药用途 |
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| EP4223751A4 (en) * | 2020-09-30 | 2024-11-27 | Humanwell Healthcare (Group) Co., Ltd. | BENZAMIDE COMPOUND AND ITS USE |
| WO2022112490A1 (en) | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| JP2023550830A (ja) | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体 |
| CN116745284A (zh) | 2020-11-27 | 2023-09-12 | 奇斯药制品公司 | 作为p2x3抑制剂的酞嗪衍生物 |
| CN114591317A (zh) * | 2020-12-04 | 2022-06-07 | 武汉人福创新药物研发中心有限公司 | P2x3抑制剂及其用途 |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
| CN116396285A (zh) * | 2022-01-04 | 2023-07-07 | 上海华汇拓医药科技有限公司 | 氘代四氢呋喃类化合物制备及其应用 |
| US12024285B1 (en) | 2022-03-10 | 2024-07-02 | Skypad Tech, Inc. | Modular mobility system including thrusters movably connected to a support structure |
| EP4501929A4 (en) * | 2022-03-29 | 2026-04-08 | Humanwell Healthcare Group Co Ltd | P2X3 INHIBITOR COMPOUND, SALT OF THEREOF, POLYMORPHIC OF THEREOF AND ASSOCIATED USES |
| WO2024131948A1 (zh) * | 2022-12-22 | 2024-06-27 | 人福医药集团股份公司 | 制备p2x3抑制剂的方法 |
| JP2026517300A (ja) | 2023-05-22 | 2026-05-28 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤を調製するための方法および中間体 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
| AU2024410803A1 (en) * | 2023-12-29 | 2026-07-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Solid dispersion of p2x3 receptor antagonist and preparation process thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5198256B2 (ja) | 2005-05-04 | 2013-05-15 | エボテク エージー | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
| ES2596706T3 (es) | 2006-06-29 | 2017-01-11 | F. Hoffmann-La Roche Ag | Arilamidas con sustitución de tetrazol |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| JP5084839B2 (ja) * | 2006-11-09 | 2012-11-28 | エフ．ホフマン−ラ ロシュ アーゲー | チアゾール及びオキサゾール置換アリールアミド |
| WO2008123963A1 (en) | 2007-04-02 | 2008-10-16 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| US8076345B2 (en) | 2007-04-17 | 2011-12-13 | Evotec Ag | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| TW200906826A (en) * | 2007-06-12 | 2009-02-16 | Genelabs Tech Inc | Anti-viral inhibitors and methods of use |
| EP2215048B1 (en) | 2007-10-31 | 2015-10-28 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| BR122019016794B8 (pt) | 2007-12-17 | 2021-07-27 | Hoffmann La Roche | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune |
| ES2570628T3 (es) | 2007-12-17 | 2016-05-19 | Hoffmann La Roche | Nuevas arilamidas con sustitución imidazol |
| KR101405746B1 (ko) | 2007-12-17 | 2014-06-10 | 에프. 호프만-라 로슈 아게 | 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도 |
| DK2234976T3 (da) | 2007-12-17 | 2013-06-24 | Hoffmann La Roche | Nye pyrazol-substituerede arylamider |
| WO2009110985A2 (en) * | 2008-02-29 | 2009-09-11 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| CA2741666C (en) * | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| BRPI0922645A2 (pt) | 2008-12-16 | 2019-09-24 | Hoffmann La Roche | "arilamidas tiadiazol substituídas". |
| EP2445868B1 (en) | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
| CA2754654A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel oxazolone and pyrrolidinone-substituted arylamides |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| US9562041B2 (en) * | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| KR102120513B1 (ko) | 2013-01-31 | 2020-06-08 | 네오메드 인스티튜트 | 이미다조피리딘 화합물 및 이의 용도 |
| CU24411B1 (es) | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| SG11202011010YA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
-
2015
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 MX MX2020005909A patent/MX387478B/es unknown
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 MX MX2017007658A patent/MX377651B/es active IP Right Grant
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko not_active Withdrawn
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt not_active IP Right Cessation
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh not_active Expired - Fee Related
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active Active
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh not_active Expired - Fee Related
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja not_active Expired - Fee Related
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en not_active Ceased
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh not_active IP Right Cessation
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
-
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
-
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
-
2019
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en not_active Expired - Fee Related
-
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
-
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown
-
2023
- 2023-04-09 JO JOJO/P/2023/0073A patent/JOP20230073A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000182A (es) | Benzamidas sustituidas con 1,3tiazol2ilo | |
| CL2017000287A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| DOP2016000253A (es) | Nuevos compuestos | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
| CU20170134A7 (es) | 2-tiopirimidinonas | |
| UY36350A (es) | Compuesto derivado de pirazol para tratamiento o prevención de la enfermedad de chagas. |